All In Biotech

Drug Trial Radar · NCT05185011

Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function

A Phase I Clinical Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild Liver Insufficiency, Moderate Liver Insufficiency and Normal Liver Function

Last checked: Nov 20, 2026Latest source record: Mar 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Dec 16, 2021

Primary completion

Feb 6, 2022

Study completion Feb 6, 2022

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
Collaborators
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
First posted
Jan 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study aims to investigate and compare the effect of TPN171H on subjects with mild and moderate hepatic impairment compared to healthy subjects.

Conditions

  • Erectile Dysfunction
  • Pulmonary Arterial Hypertension

Interventions

  • TPN171HDrug

    10 mg TPN171H tablets,single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax)Time frame: 72 hours after dosing
  2. Area under the plasma concentration versus time curve from single dosing time extrapolated to infinity(AUC0-∞)Time frame: 72 hours after dosing
  3. Area under the plasma concentration versus time curve from the last time of dosing to the last measurable concentration (AUC0-t)Time frame: 72 hours after dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Jilin University

    Changchun, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.